Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pediatric Movement Disorders of Unknown Etiology in Vietnam (VPeMD) (VPeMD)

8. juli 2026 oppdatert av: Nguyen Bich Y Linh, University of Medicine and Pharmacy at Ho Chi Minh City

Phenotypic and Genotypic Characterization of Pediatric Movement Disorders of Unknown Etiology in Vietnam

This observational patient registry aims to describe the clinical phenotypes and genetic findings of Vietnamese children with movement disorders of unknown etiology. Eligible participants are children with clinically confirmed movement disorders after evaluation by pediatric neurology specialists and after exclusion of clear acquired causes.

The study will collect clinical data, neurological examination findings, available laboratory and imaging results, and video recordings of abnormal movements when consent is provided. Blood samples will be collected for whole-exome sequencing and related genetic analysis. Genetic variants will be classified according to accepted clinical genetics standards and compared with the patients' clinical phenotypes.

The study is expected to improve understanding of the phenotypic and genotypic spectrum of pediatric movement disorders in Vietnam, support genetic counseling, and evaluate how genetic results may influence diagnosis, follow-up, prognosis, and treatment planning.

Studieoversikt

Detaljert beskrivelse

Movement disorders in children represent a heterogeneous group of neurological conditions that include dystonia, chorea, ataxia, myoclonus, tremor, tics, parkinsonism, and mixed movement disorders. The underlying causes are highly diverse and include genetic, metabolic, neurodegenerative, structural, immune-mediated, and acquired disorders. However, a substantial proportion of pediatric patients remain without a definitive diagnosis after standard clinical evaluation and routine investigations.

Recent advances in next-generation sequencing technologies, particularly whole-exome sequencing, have significantly improved the diagnostic yield in pediatric movement disorders and have contributed to the identification of novel disease-causing genes and genotype-phenotype correlations. Nevertheless, data regarding the clinical and genetic spectrum of pediatric movement disorders in Vietnam remain limited.

The VPeMD registry is a prospective observational patient registry designed to collect standardized clinical and genetic data from Vietnamese children with movement disorders of unknown etiology. Participants will undergo detailed clinical evaluation by pediatric neurology specialists, including assessment of movement phenomenology, neurological findings, developmental history, family history, neuroimaging findings, laboratory investigations, and treatment history.

Biological samples will be collected for genetic analysis, including whole-exome sequencing and additional molecular investigations when appropriate. Genetic variants will be interpreted according to internationally accepted standards and correlated with clinical manifestations.

The study aims to characterize the phenotypic and genotypic spectrum of pediatric movement disorders in Vietnam, evaluate diagnostic yield of genetic testing, identify genotype-phenotype correlations, and assess the potential impact of genetic diagnosis on patient management, prognosis, genetic counseling, and future therapeutic strategies.

Studietype

Observasjonsmessig

Registrering (Antatt)

50

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Rekruttering
        • Children's Hospital 1, Ho Chi Minh City
        • Ta kontakt med:
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Rekruttering
        • University Medical Center Ho Chi Minh City
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Vietnamese children with clinically confirmed movement disorders of unknown etiology who are evaluated or treated at University Medical Center Ho Chi Minh City or Children's Hospital 1. Participants will be enrolled after clinical assessment by pediatric neurology specialists and after informed consent is obtained from legal guardians and/or participants when appropriate.

Beskrivelse

Inclusion Criteria:

  • Children younger than 18 years old.
  • Patients with clinically confirmed movement disorders based on direct examination and/or video review by at least two pediatric neurology specialists.
  • Patients with movement disorders of unknown etiology after appropriate neurological evaluation and exclusion of clear acquired causes.
  • Patients evaluated or treated at University Medical Center Ho Chi Minh City or Children's Hospital 1 during the study period.
  • Patients and/or legal guardians who provide written informed consent for study participation and genetic testing.

Exclusion Criteria:

  • Patients with isolated or transient primary tic disorders.
  • Patients with a confirmed acquired cause of movement disorder.
  • Patients or legal guardians who decline participation or withdraw from the study.
  • Patients with insufficient clinical information or unavailable biological samples for genetic analysis.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Vietnamese Pediatric Movement Disorder Cohort
Vietnamese children with clinically confirmed movement disorders of unknown etiology who meet the study eligibility criteria and are enrolled in the VPeMD registry. Participants will undergo standardized clinical data collection and genetic testing using whole-exome sequencing.
Whole-exome sequencing will be performed on DNA extracted from peripheral blood samples to identify genetic variants associated with pediatric movement disorders. The test is used for genetic analysis and genotype-phenotype correlation in this observational registry and is not assigned as a treatment intervention.
Andre navn:
  • Neste generasjons sekvensering
  • WES

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical Phenotypes of Pediatric Movement Disorders
Tidsramme: At enrollment
Distribution of clinical movement disorder phenotypes among enrolled participants, including dystonia, chorea, ataxia, myoclonus, tremor, parkinsonism, stereotypies, and mixed movement disorders, based on pediatric neurology assessment and clinical records.
At enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Diagnostic Yield of Whole-Exome Sequencing
Tidsramme: From enrollment to return of genetic results, up to 12 months
Proportion of enrolled participants with pathogenic or likely pathogenic genetic variants identified by whole-exome sequencing and related genetic analysis.
From enrollment to return of genetic results, up to 12 months
Genotype-Phenotype Correlation
Tidsramme: From enrollment to completion of clinical and genetic data analysis, up to 24 months

Correlation between identified genetic variants and clinical phenotypes of pediatric movement disorders will be assessed.

Genetic findings will be obtained from WES. Clinical phenotypes will be characterized using standardized neurological assessments, including movement disorder classification, age at onset, symptom distribution, disease progression, neurological comorbidities, developmental status, and neuroimaging findings when available.

The correlation between genotype and phenotype will be evaluated by comparing identified genetic variants with clinical characteristics of enrolled participants.

From enrollment to completion of clinical and genetic data analysis, up to 24 months
Impact of Genetic Diagnosis on Clinical Management
Tidsramme: From return of genetic results to follow-up assessment, up to 12 months
Proportion of participants whose diagnosis, prognosis, follow-up plan, genetic counseling, or treatment strategy is changed after genetic testing results become available.
From return of genetic results to follow-up assessment, up to 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Linh B. Y Nguyen, MD, MSc, PHD Candidate, University of Medicine and Pharmacy at Ho Chi Minh City

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. april 2026

Primær fullføring (Antatt)

1. februar 2028

Studiet fullført (Antatt)

31. januar 2029

Datoer for studieregistrering

Først innsendt

1. juli 2026

Først innsendt som oppfylte QC-kriteriene

8. juli 2026

Først lagt ut (Faktiske)

10. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • UMP-VPeMD-26298

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared because the study involves pediatric participants and sensitive genetic data. Data sharing is restricted by the approved ethics protocol, informed consent, and privacy considerations related to clinical and genomic information.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere